Mainz Biomed N.V. announces a reverse stock split, adopting an innovative strategy as part of its recent partnership with the medical technology giant, Thermo Fisher Scientific Inc.. This agreement aims to promote the development of next-generation colorectal cancer screening tests, thereby strengthening Mainz Biomed’s position in the early diagnostics market. Thanks to this collaboration, the two companies will pool their expertise to improve the solutions offered to patients in the fight against cancer.

Mainz Biomed N.V. recently announced a reverse reverse stock split at the rate of one action for 40, which will be effective on December 3. This decision comes following a strategic partnership with Thermo Fisher Scientific Inc., aiming to develop a colorectal cancer screening product new generation. Through this collaboration, Mainz Biomed and Thermo Fisher join forces to develop tests based onmRNA, aimed at improving the early detection of colorectal cancer, with a particular focus on precancerous lesions. The agreement combines Thermo Fisher’s technologies and information systems with Mainz Biomed’s innovations to create more effective screening solutions. This initiative comes against a backdrop where Mainz Biomed has already recorded an increase in revenue and a reduction in operational losses during the first half of 2024.

Mainz Biomed N.V. recently announced a consolidation of shares reversed at a rate of one for forty, a decision which will take effect on December 3. This maneuver comes in a context where the company aims to optimize its financial structure after establishing a strategic partnership with the medical technology giant, Thermo Fisher Scientific Inc.. Magnet to strengthen its positioning on the market early detection of cancer, Mainz Biomed seems confident in the impact of this partnership on its future performances.

The challenges of the partnership with Thermo Fisher

The recently signed partnership between Mainz Biomed And Thermo Fisher Scientific aims to develop next generation colorectal cancer screening products. Through this collaboration, the two companies aim to commercialize innovative solutions based on Thermo Fisher’s advanced technologies. The project focuses on creating tests based on mRNA, capable of improving the detection of precancerous lesions such as advanced adenomas, thus promising early results for patients.

A significant advance in colorectal cancer screening

By choosing to collaborate with a leader like Thermo Fisher, Mainz Biomed is making considerable progress in the optimization of its flagship product, ColoAlert. This non-invasive test allows reliable results to be obtained in a short time, a crucial aspect for the public health. The new proprietary buffer used in the test helps limit retesting, making the process more efficient while preserving the quality of results.